FDA Approves Eli Lilly's Foundayo Weight Loss Pill with Fewer Restrictions
The U.S. Food and Drug Administration has approved Foundayo, a new GLP-1 weight loss pill developed by Eli Lilly. This approval marks the second GLP-1 pill for weight loss, following the recent approval of Novo Nordisk's Wegovy pill. Foundayo offers a significant advantage as it can be taken at any time of day without restrictions on food and water, unlike Wegovy, which must be taken in the morning before meals. Eli Lilly's Foundayo is part of a growing range of obesity treatments that include injectable drugs like Zepbound and Mounjaro. The approval comes as part of a deal with the Trump administration, allowing for competitive pricing and broader access, with the pill priced at $149 per month for the lowest doses. 
